GRCL Gracell Biotechnologies Inc. Stock Quote

GRCL [NASD]

Index	-	P/E	-	EPS (ttm)	-0.65	Insider Own	-	Shs Outstand	67.35M	Perf Week	-5.58%
Market Cap	774.52M	Forward P/E	-	EPS next Y	-1.70	Insider Trans	-	Shs Float	2.20M	Perf Month	-19.69%
Income	-42.50M	PEG	-	EPS next Q	-0.21	Inst Own	6.30%	Short Float	17.91%	Perf Quarter	-62.38%
Sales	-	P/S	-	EPS this Y	-36.70%	Inst Trans	-	Short Ratio	4.66	Perf Half Y	-
Book/sh	-	P/B	-	EPS next Y	-49.10%	ROA	-	Target Price	-	Perf Year	-
Cash/sh	1.78	P/C	6.47	EPS next 5Y	-	ROE	-	52W Range	10.52 - 33.70	Perf YTD	-54.11%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-65.88%	Beta	-
Dividend %	-	Quick Ratio	8.70	Sales past 5Y	-	Gross Margin	-	52W Low	9.32%	ATR	1.07
Employees	160	Current Ratio	8.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	30.34	Volatility	8.67% 8.17%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.24	Prev Close	11.50
Shortable	Yes	LT Debt/Eq	-	Earnings	Mar 09 AMC	Payout	-	Avg Volume	84.57K	Price	11.50
Recom	1.50	SMA20	-9.37%	SMA50	-33.11%	SMA200	-43.40%	Volume	20,591	Change	0.00%

Feb-03-21

Initiated

Citigroup

Buy

$35

Feb-02-21

Initiated

Wells Fargo

Overweight

$33

Feb-02-21

Initiated

Piper Sandler

Overweight

$40

Feb-02-21

Initiated

Jefferies

Buy

$30

Apr-30-21 05:32PM	Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May GlobeNewswire
Apr-23-21 06:00PM	Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2020 GlobeNewswire
Apr-10-21 09:33AM	Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting PR Newswire
Apr-08-21 05:53AM	What Type Of Shareholders Make Up Gracell Biotechnologies Inc.'s (NASDAQ:GRCL) Share Registry? Simply Wall St. +7.27%
Apr-05-21 08:00AM	Gracell Biotechnologies to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-31-21 08:45AM	Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S. PR Newswire
08:00AM	Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL PR Newswire
Mar-17-21 08:00AM	Gracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access Day GlobeNewswire
Mar-10-21 05:15AM	Gracell Biotechnologies Inc - ADR to Host Earnings Call ACCESSWIRE
Mar-09-21 04:01PM	Gracell Biotechnologies Reports Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results and Provides Corporate Update GlobeNewswire +7.26%
Jan-29-21 08:30PM	Tegna, Clear Channel Outdoor See Activist Action Barrons.com
Jan-19-21 06:30AM	Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL PR Newswire -6.25%
Jan-15-21 08:00AM	Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products PR Newswire
Jan-13-21 08:00AM	China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL PR Newswire
Jan-08-21 01:55AM	Gracell Biotechnologies Announces Pricing of Initial Public Offering PR Newswire

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience